Speaker:
Title:
Combination Immunotherapy Engaging Innate and Adaptive Immunity
Abstract:
Checkpoint blockade has shown that endogenous immune responses can elicit durable regressions in advanced tumors, but these responses are confined to a minority of patients. This outcome is partly due to the network of immunosuppressive pathways present in advanced tumors, which are unlikely to be overcome by intervention at a single checkpoint. Generating a counter-directed network of pro-immunity signals through combination immunotherapies may be a powerful strategy for improving efficacy of immunotherapies in the clinic.